| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF11A |
| Uniprot No | Q9Y6Q6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-212aa |
| 氨基酸序列 | IAPPCTSEKHYEHLGRCCNKCEPGKYMSSKCTTTSDSVCLPCGPDEYLDSWNEEDKCLLHKVCDTGKALVAVVAGNSTTPRRCACTAGYHWSQDCECCRRNTECAPGLGAQHPLQLNKDTVCKPCLAGYFSDAFSSTDKCRPWTNCTFLGKRVEHHGTEKSDAVCSSSLPARKPPNEPHVYLP |
| 预测分子量 | 50.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFRSF11A(RANK)重组蛋白的3篇示例文献(内容为示例性概括，非真实文献)：
1. **"Expression and functional characterization of recombinant human TNFRSF11A in mammalian cells"**
- 作者：Smith A, et al.
- 摘要：研究在大肠杆菌和哺乳动物表达系统中制备重组TNFRSF11A蛋白，验证其与RANKL(配体)的结合活性及激活下游NF-κB信号通路的能力。
2. **"Structural insights into the extracellular domain of TNFRSF11A and its interaction with RANKL"**
- 作者：Li X, et al.
- 摘要：通过X射线晶体学解析重组TNFRSF11A胞外区结构，揭示其与RANKL结合的分子机制，为骨代谢疾病药物开发提供结构基础。
3. **"Recombinant soluble TNFRSF11A inhibits osteoclastogenesis in vitro and prevents bone loss in murine models"**
- 作者：Chen H, et al.
- 摘要：利用重组可溶性TNFRSF11A蛋白作为RANKL的竞争性抑制剂，在体外抑制破骨细胞分化，并在骨质疏松小鼠模型中减少骨吸收。
(注：以上文献为示例，实际研究中建议通过PubMed或Web of Science检索具体论文。)
TNFRSF11A recombinant protein, also known as receptor activator of nuclear factor kappa-B (RANK), is a key member of the tumor necrosis factor receptor superfamily (TNFRSF). It is a type I transmembrane protein primarily expressed on osteoclast precursors, dendritic cells, and certain cancer cells. Structurally, it contains extracellular cysteine-rich domains critical for ligand binding, a transmembrane region, and intracellular signaling motifs that interact with adaptor proteins like TRAFs (TNF receptor-associated factors).
The RANK protein plays a pivotal role in bone metabolism and immune regulation. Its interaction with RANK ligand (RANKL) activates downstream NF-κB and MAPK signaling pathways, driving osteoclast differentiation, survival, and bone resorption. This RANK/RANKL/OPG (osteoprotegerin) axis is central to maintaining bone homeostasis, with dysregulation linked to osteoporosis, rheumatoid arthritis, and cancer-related bone metastases.
Recombinant TNFRSF11A is typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. The purified protein often includes epitope tags (e.g., His-tag) for isolation and detection. Researchers utilize it to study RANK signaling mechanisms, screen therapeutic inhibitors targeting bone disorders, or develop diagnostic assays for autoimmune diseases. In pharmaceutical development, it serves as a critical tool for validating biologics like denosumab, a RANKL-targeting monoclonal antibody used clinically to prevent pathological bone loss.
Quality-controlled batches are characterized through SDS-PAGE, Western blotting, and functional assays measuring interactions with RANKL. Its applications extend to modeling bone remodeling processes, investigating tumor microenvironment crosstalk, and exploring immune tolerance mechanisms. Recent studies also implicate RANK signaling in mammary gland development and breast cancer progression, expanding its biomedical relevance beyond skeletal biology.
×
